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Abstract 
Human IM-9 lymphoblasts synthesize IGF-I and express IGF-I receptors, IGF-II/M6P receptors and GH receptors. We have studied 
the regulation of mRNA expression of IGF-I, IGF-I receptors, IGF-II/M6P receptors and GH receptors in IM-9 cells upon 
serum-withdrawal and re-addition of serum. IM-9 cells were cultured in RPMI-1640 medium with or without serum for various periods of 
time. RNA was prepared using guanidinium thiocyanate and CsC1. Antisense riboprobes for human IGF-I, IGF-I receptor, IGF-II/M6P 
receptor, GH receptor and for comparison for human beta-actin were synthesized and labeled with 32p. Protected fragments of 379 bases 
and of 420 and 350 bases with the IGF-I receptor and with the IGF-I probe respectively and protected fragments of 670 bases and of 51 
and 121 bases with the GH receptor and with the beta-actin probe were detected. For the human IGF-II/M6P receptor probe protected 
fragments of 260 bases were visualized in RNA samples. The amount of mRNA present in each lane (10/zg total RNA) was determined 
by computed ensitometry. The amount of IGF-I mRNA expressed by IM-9 cells decreased rapidly (within two hours) and dramatically 
(more than 120%) after the withdrawal of serum and increased significantly (220%) after the re-addition of serum. This increase of IGF-I 
mRNA preceded the increase: in cell number that was seen after 48 h of medium change. Conversely, the expression of IGF-I receptor 
mRNA and beta-actin mRNA increased by more than 250% after the withdrawal of serum within 2 and 8 h respectively, while GH 
receptor mRNA fell within 2-4 h. The expression of IGF-II/M6P receptor mRNA continued to increase throughout the duration of the 
cell culture experiment. We conclude that IGF-I and IGF-I receptor mRNAs are regulated in an opposite direction in serum-deprived 
IM-9 lymphoblasts. In addition, GH receptor mRNA expression parallels IGF-I mRNA expression. 
Keywords: Insulin-like growth factor; Insulin-like growth factor eceptor; Growth hormone receptor; IGF-II/mannose-6-phosphate rec ptor; Beta-actin; 
IM-9 lymphoblast 
1. Introduction 
The growth hormone-insulin-like growth factor axis 
plays a key role in the hormonal regulation of growth and 
cell proliferation [1-3]. GH binds to a high affinity cell 
surface receptor that signals its biologic function through a 
phosphorylation cascade involving a family of tyrosine 
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kinases ( JAK kinases). GH receptors are mainly expressed 
in human liver but are also found in many other tissues [4]. 
The insulin-like growth factors ( IGF-I  and IGF-II) are 
polypeptides which share homology with insulin in respect 
to amino acid sequence and protein structure. The IGFs 
exert insulin-like metabolic effects in vitro and in vivo. 
The IGFs are potent mitogens for cells in culture. IGF-I  
mediates most of the anabolic effects of pituitary growth 
hormone, whereas IGF-I I  is thought to play an important 
role as a fetal growth factor. Recent experimental evidence 
also suggests that IGF-I I  might be an important regulator 
of the lysosomal degradation pathway [1,2]. The IGFs bind 
to at least two classes of high affinity receptors that are 
present on many cells and tissues. The IGF-I receptor is a 
heterotetramer that closely resembles the insulin receptor 
and mediates most if not all of the IGF-induced biologic 
318 Y. Yang et al. / Biochimica et Biophysica Acta 1310 (1996) 317-324 
effects. The IGF-I receptor is a tyrosine kinase that signals 
its biologic response through a cascade of phosphorylation 
events that include phosphorylation f insulin-responsive 
substrate-1 (IRS-I), phosphatidyl-inositol-3-kinase (PI3- 
kinase) and mitogen-activated protein kinases (MAP ki- 
nases) [5,6]. The IGF-II/M6P receptor is a bifunctional 
binding protein that binds both IGF-II and mannose-6- 
phosphate bearing lysosmal enzymes at distinct binding 
sites. The two classes of ligands that bind to the IGF- 
I I /M6P receptor reciprocally inhibit binding of the other 
class of ligand [7-11 ]. 
Little is known as to the regulation of GH receptor and 
IGF receptor expression i vivo and in vitro. While insulin 
and developmental f ctors seem to be the major regulators 
of IGF-II/M6P receptor expression [9], regulation of IGF-I 
receptor expression is poorly understood. GH and IGF-I 
itself have been implicated in the regulation of IGF-I 
receptor protein expression in cells in culture [12-14]. It 
has also been suggested that IGF-I and its receptor are 
regulated in an opposite way [15-18]. There are no studies 
that report upon the concomitant regulation of IGF-I and 
the IGF receptors either in vivo or in vitro. 
We have used the IM-9 lymphoblast cell line to exam- 
ine the regulation of IGF-I and of IGF-I receptor gene 
expression during proliferative phases of human cells [3]. 
For comparison we have also measured the presence of 
beta-actin RNA, growth hormone receptor RNA and IGF- 
I I /M6P receptor RNA in human IM-9 lymphoblasts dur- 
ing serum-deprivation a d after serum re-addition to cell 
cultures. The results obtained suggest that the GH receptor 
may be involved in regulating IGF-I production by IM-9 
cells. In addition, our data give evidence as to a putative 
compensatory up-regulatory mechanism involving the 
IGF-I receptor after serum withdrawal and decrease of 
endogenous IGF-I expression. 
2. Materials and methods 
2.1. Peptides and cDNA probes 
The following probes were used in solution hybridisa- 
tion/RNase protection assays and were a kind gift from 
Dr. C.T. Roberts, Bethesda: a 442 bases hlGF-I probe [19], 
and a 379 bases (394 bases full-length probe) hlGF-I 
receptor probe. The hlGF-II/M6P receptor probe was 260 
nucleotides in length with 250 bases of the bases comple- 
mentary to the IGF-II/M6P receptor mRNA. The human 
GH receptor DNA probe (670 bases) was obtained from 
Dr. Guo, Shanghai, People's Republic of China [3,20]. 
Recombinant human growth hormone (GH) was kindly 
donated by NovoNordisk, Mainz, Germany. IGF-I was 
kindly donated by Dr. Steinkamp, Pharmacia, Kabi Peptide 
Hormones, Erlangen, Germany. Interleukin-1 beta (IL-1 
beta) was purchased from Sigma Chemicals, St. Louis, 
USA. 
2.2. Cell culture 
IM-9 cells were obtained from ATTC, Rockville, USA, 
and were grown in RPMI-1640 medium (Seromed, Berlin, 
Germany) containing 10% FCS at 37°C in 5% CO2. Cells 
were subcultured every 2-3 days. For experiments cells 
were washed 3 times with serum-free RPMI-1640 medium 
and then were kept serum-free for 2, 4, 8, 12, 24, 48, and 
72 h as indicated. In a subset of experiments cells were 
cultured in serum-free RPMI-1640 medium with or with- 
out hGH (100 ng/ml), or IGF-I (50 ng/ml) or IL-1 beta 
(5 U/ml). Where indicated cells were re-exposed to 
serum-containing medium (10% FCS) after they had been 
cultured in serum-free medium for 24 h for the indicated 
time periods. 
2.3. Cell proliferation 
Viable cells were identified and counted after the indi- 
cated times in culture after Trypan blue staining (Sigma, 
Heidelberg, Germany) using a hemocytometer chamber. 
Cell numbers are expressed as cells per ml of culture 
medium. 
2.4. RNA extraction 
Cells were harvested in 4 M guanidinium thiocyanate 
(Fluka, Switzerland) with 25 mM sodium acetate and 
0.835% beta-mercaptoethanoi. The suspension was ho- 
mogenized with a polytron (Kinematika, Germany) for 15 
s. The RNA was pelleted by ultra-centrifugation n 5.7 M 
CsC1 solution with 25 mM sodium acetate in polyallomer 
tubes (Beckman, Munich, Germany) in a Beckman Ti-50 
rotor for 18-23 h at 24°C. The RNA pellet was dissolved 
in DEPC-treated water and precipitated in ethanol overnight 
at -20°C. The amount of RNA was calculated by mea- 
surement of optical density at 260 nm. The ratio of ab- 
sorbance at 260 nm and 280 nm was routinely greater than 
1.7. The quality of the RNA was further examined by 
electrophoresis in 0.8% TBE-agarose, where the bands of 
the 28S and of the 18S rRNA showed a typical ratio and 
clear shape [21,22]. 
2.5. Solution hybridization/RNase protection assay 
A pGEM-3 plasmid containing a 442 bases PstI-RsaI 
fragment of the human IGF-I cDNA which included an 18 
bases GC tail, 89 bases of 5'UTR derived from exon 1, 
and 329 bases encoding the pre, B, C, A, D and part of the 
E domain was linearized with HindlII and the antisense 
riboprobe was transcribed using T7 RNA polymerase. 
Identity of the IGF-I cDNA probe was confirmed by 
partial sequencing of the probe (courtesy of Dr. J. Haenze, 
Molecular Biology Laboratory, Children's Hospital, 
Giessen, Germany). An antisense IGF-I receptor RNA 
probe was transcribed from a 379 bases SalI-EcoRI hu- 
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man IGF-I receptor eDNA fragment. An antisense ribo- 
probe containing 250 bases complementary to the IGF- 
I I /M6P receptor eDNA and 10 bases of PGEM-2 se- 
quence was generated with T7 RNA polymerase. A 670 
bases EcoRI-HindIII eDNA fragment derived from the 
human growth hormone receptor gene, exon 10, was cloned 
in the PTZ 19u vector. This construct was linearized with 
EcoRI, and the antisense RNA was generated using T7 
RNA polymerase. A 50 bases SalI-AvaI human beta-actin 
eDNA fragment was also transcribed. Riboprobes were 
synthesized and labeled u'sing the Riboprobe Gemini II 
Core system (Promega, Heidelberg, Germany, Cat. P1270) 
and 32p (Amersham, Braunschweig, Germany). Solution 
hybridization was performed with antisense RNA probes 
(approx. 200 000 cpm 32 P-UTP labeled) at 45°C overnight 
in a buffer containing 75% formamide, Tris 20 mM (pH 
7.6), EDTA 1 mM (pH 8.0), NaCI 0.4 M, 0.1% SDS. After 
hybridization samples were digested with RNase (RNase 
A, and RNase TI, Boehringer Mannheim, Mannheim, 
Germany), the protected fragments were extracted with 
phenol-choloroform, precipitated with ethanol, and elec- 
trophoresed on an 8% polyacrylamide-8 M urea denaturing 
gel [20]. Protected radiolabeled fragments were identified 
by exposing the gels to Kodak X-AR films with DuPont 
enhancer screens at - 70°(; for 1-11 days [21,22]. 
2.6. Quantitation and statistical analysis 
Autoradiograms of polyacrylamide gels were scanned 
using the Biolmage system (TF-3X, Biolmage system, 
USA). Density of the protected bands was measured and 
relative optical densities (arbitrary units) of the respective 
bands from at least three independent experiments (inde- 
pendent cell cultures) were compared using unpaired Stu- 
dent's t-test. Equal loading of the gels was assured by 
parallel analysis of RNA preparations by electrophoresis in 
0.8% TBE-agarose and methylene blue staining of the gels 
[21,22]. In addition, the pattern of/3-actin RNA expression 
was analyzed in the same gels as were the RNA species of 
interest, fl-actin RNA expression showed a consistent and 
reproducible pattern also indicating equal loading of the 
gels. 
3. Results 
3. I. Cell proliferation 
When IM-9 cells were placed serum-free, cells slowly 
proliferated with a significant increase in cell number 
being measured after 48 h of culture (Fig. 1). Re-addition 
of serum after 24 h of serum free culture led to a doubling 
of cell numbers within 24 h and further proliferation of 
cells after 48 and 72 h of s, erum stimulation. In the absence 
of serum, neither GH, nor IGF-I nor IL-I beta at the 
concentrations u ed had an effect upon proliferation of 
IM-9 lymphoblasts (data not shown). 
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Fig. l. Proliferation of human IM-9 lymphoblasts after serum removal 
and serum re-addition. IM-9 cells were cultured in suspension cultures as 
described in Section 2 and cell numbers were determined using Trypan 
blue exclusion staining and a hemocytometer chamber. The data points 
represent mean + S.D. of 3 independent experiments. After re-addition of 
serum there was a doubling of cell numbers after 24 h. 
3.2. Expression of IGF-I and IGF-I receptor RNA after 
serum deprivation and serum re-addition 
When RNA from IM-9 cells was analyzed for IGF-I 
RNA transcripts using RNase protection/solution hy- 
bridization assays, a 420 and a 350 bases protected IGF-I 
specific band were visualized on autoradiograms of poly- 
acrylamide gels (Fig. 2). When a 32 P-labeled human IGF-I 
receptor iboprobe was used in RNase protection assays 
instead of the human IGF-I probe, a faint, 379 bases IGF-I 
receptor specific band was detected (Fig. 3). While IGF-I 
RNA expression decreased very rapidly and dramatically 
after 2 h of serum deprivation, IGF-I receptor RNA in- 
creased: after only 2 h of serum deprivation IGF-I receptor 
RNA transcripts as measured by solution hybridization 
assays and analysis of protected bands by computerized 
densitometry had almost increased 5-fold and reached a 
maximum after 72 h of serum deprivation (Fig. 4A,B). The 
expression of beta-actin RNA visualized as 121 bases and 
51 bases protected fragments also increased steadily after 
serum deprivation of IM-9 lymphoblasts (Figs. 2, 3 and 5, 
and data not shown). Re-addition of serum after 24 h of 
serum free culture for various periods of time (24, 48 and 
72 h) led to a significant increase in IGF-I RNA at 24, 48 
h and 72 h but did not further change IGF-I receptor RNA 
(Figs. 2-4A,B). Addition of GH (100 ng/ml), IGF-I (50 
ng/ml) or II-1 beta (5 IU/ml) did not alter the change in 
IGF-I and IGF-! receptor RNA expression detected uring 
the serum deprivation period (data not shown). 
3.3. Expression of GH receptor and IGF-H / M6P receptor 
RNA after serum deprivation and serum re-addition 
RNase protection/solution hybridization assays using a 
radiolabeled human GH receptor iboprobe and IM-9 cell 
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RNA revealed a 670 bases protected GH receptor specific 
band on autoradiograms of polyacrylamide gels (Fig. 5). 
When a 32p-labeled human IGF-II/M6P receptor ibo- 
probe was used in RNase protection assays a 260 bases 
IGF-II/M6P receptor specific band was detected (Fig. 6). 
GH receptor RNA expression decreased rapidly and dra- 
matically after 2 h of serum deprivation, stayed stably low 
for 24 h and increased sharply at 48 h of serum depriva- 
tion. These changes were in contrast o the changes of 
beta-actin mRNA expression which steadily increased 
within 8 h of serum deprivation (Fig. 7). IGF-II/M6P 
receptor RNA increased gradually and steadily throughout 
the duration of the experiment, independent of whether or 
not serum was readded (Fig. 6 and data not shown). Again, 
the density of beta-actin specific protected bands (51 bases 
protected band) increased in all experiments gradually and 
steadily with the duration of the experiments, a pattern that 
was similar to the pattern observed with the IGF-II/M6P 
receptor specific band at 260 bases (Fig. 6 and data not 
shown). Addition of GH (100 ng/ml), IGF-I (50 ng/ml) 
or I1-1 beta (5 IU/ml) again had no influence upon the 
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Fig. 2. Serum-deprivation f IM-9 lymphoblasts leads to a decrease in 
IGF-I RNA expression. Cells were cultured serum-free for various peri- 
ods of time. In a subset of cell cultures erum was readded (24, 48 and 72 
h of culture after serum re-addition, last 3 lanes). Solution 
hybridisation/RNase protection was carried out as described in Section 2. 
St, molecular weight markers (bases); C1, 32p-riboprobe incubated with 
RNases; C2, riboprobe alone. Two RNA species of 420 and 350 bases 
respectively were protected (upper arrow). The relatively low abundance 
of IGF-I RNA in comparison to beta-actin RNA (lower arrows) is 
demonstrated. 
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Fig. 3. Serum-deprivation f IM-9 lymphoblasts leads to an increase in 
IGF-I receptor RNA and beta-actin RNA expression. Cells were cultured 
serum-free for various periods of time. In a subset of cell cultures erum 
was re-added (+).  Solution hybridisation/RNase protection was carried 
out as described in Section 2. St, molecular weight markers (bases); C1, 
32p-riboprobe incubated with RNases; C2, riboprobe alone. 
pattern of changes of gene expression seen with serum 
deprivation (data not shown). 
4. Discussion 
We have used the IM-9 lymphoblast cell line to exam- 
ine the regulation of IGF-I and of IGF-I receptor gene 
expression during proliferative phases of human cells. The 
results obtained suggest that the GH receptor may be 
involved in regulating IGF-I production by IM-9 cells and 
that there is evidence as to a putative compensatory up- 
regulatory mechanism involving the IGF-I receptor after 
serum withdrawal and decrease of endogenous IGF-I ex- 
pression. 
Our data demonstrate that IGF-I and IGF-I receptor 
RNA expression i  IM-9 lymphoblasts change in an oppo- 
site direction upon serum starvation: the expression of 
IGF-I RNA species declines dramatically within 2 h after 
serum withdrawal and gradually increased after 48 h of 
culture in serum free medium. Addition of serum at 24 h 
or inclusion of hGH (100 ng/ml), or IGF-I (50 ng/ml) or 
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IL-1 beta (5 IU/ml) during the serum free conditions did 
not change IGF-I RNA expression in IM-9 lymphoblasts 
further. Since the concentrations of single stimulants used 
in these experiments is in accordance tobiologically effec- 
tive and/or physiological doses, it is most likely that IM-9 
cells do not respond to these agents under the conditions of 
our experiments. Two protected fragments of IGF-I RNA 
were detected in IM-9 cell RNA in our study. Similar 
observations were made in the human ovary [20] and also 
in IM-9 lymphoblasts [23,24]: it is thought hat multiple 
RNA species are caused by the use of different promoters 
of the IGF-I gene. Indeed, multiple transcripts of the IGF-I 
gene have been found to be expressed in IM-9 lympho- 
blasts with exon 2 being the major leader exon [24]. In 
contrast o the IGF-I RNA species, IGF-I receptor RNA 
increased rapidly after withdrawal of serum and increased 
in a continuous fashion (Fig;. 4). Such an increase in IGF-I 
receptor mRNA expression might indicate a putative com- 
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Fig. 4. Serum deprivation of IM-9 lymphoblasts leads to a decrease in 
IGF-I RNA (panel A) and an increase in IGF-I receptor RNA (panel B) 
expression. Cells were cultured serum-free for various periods of time. In 
a subset of cell cultures serum was readded (+) .  Solution 
hybridisation/RNase protection was carded out as described in Section 2. 
Autoradiographs were analyzed by computed ensitometry as described 
in Section 2. The data points represent mean + S.D. of three (panel A) or 
four (panel B) independent cultures and the representative RNAse protec- 
tion assays. 
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Fig. 5. Serum-deprivation f IM-9 lymphoblasts leads first to a rapid 
decrease and in a second phase to an increase in GH receptor RNA 
expression. Cells were cultured serum-free for various periods of time. In 
a subset of cell cultures serum was readded (+) .  Solution 
hybridisation/RNase protection was carried out as described in Section 2. 
St, molecular weight markers (bases); C1, 32p-riboprobe incubated with 
RNases; C2, riboprobe alone. The lower part of the panel shows the 
expression of beta-actin mRNA of the same experiment as analyzed in a 
parallel gel. 
pensatory up-regulatory mechanism at the receptor mRNA 
level under condit ions where IGF-I  l igand 
expression/concentrations are low. 
Conversely, changes in GH receptor mRNA initially 
paralleled the changes of IGF-I RNA that were seen upon 
the removal of serum from the cell cultures. Indeed, it has 
been shown that in EBV-transformed B-lymphoblasts from 
healthy subjects, GH regulates IGF-I production presum- 
ably through interaction with its own receptor [27]. In 
addition, the content of IGF-II/M6P receptor RNA and 
beta-actin RNA of IM-9 cells increased throughout the 
duration of the experiment in a continuous fashion. These 
changes were again observed independently of whether or 
not the cells were kept serum free or serum free with the 
addition of either IGF-I, hGH or II-1 beta. Also, the 
re-addition of serum after 24 h under serum free conditions 
did not significantly change the expression of IGF-II/M6P 
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Fig. 6. Serum-deprivation f IM-9 lymphoblasts leads to an increase in 
IGF-II/M6P receptor RNA and beta-actin RNA expression. Cells were 
cultured serum-free for various periods of time. In a subset of cell 
cultures serum was readded. Solution hybridisation/RNase protection 
was carried out as described in Section 2. St, molecular weight markers 
(bases); C1, 32p-riboprobe incubated with RNases; C2, riboprobe alone. 
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Fig. 7. Serum-deprivation f IM-9 lymphoblasts leads to a decrease and 
subsequent increase of GH receptor RNA expression. Cells were cultured 
serum-free for various periods of time. In a subset of cell cultures erum 
was readded. Solution hybridisation/RNase protection was carried out as 
described in Section 2 and computed ensitometry was used to quantitate 
the results from 3 independent experiments (3 independent cell culture 
studies). Data points are means + S.D. 
receptor RNA, GH receptor RNA and beta-actin RNA. 
The changes of beta-actin expression during serum with- 
drawal in these experiments make the use of beta-actin as 
a control for equal loading of the gels rather complicated. 
However, the reproducible pattern of beta-actin RNA ex- 
pression can serve both for a measurement of equal load- 
ing and for a means to determine the reproducibility of the 
cell culture experiments hemselves. 
We conclude that IGF-I and GH receptor RNA are 
expressed in parallel and serum deprivation leads to a 
rapid and dramatic decline of both IGF-I and GH receptor 
RNA. In a second phase of changes in IGF-I and GH 
receptor RNA expression, increased transcription of the 
two genes was observed after approx. 24 h of serum 
starvation. Interestingly, this increase of IGF-I and GH-re- 
ceptor RNA expression coincides with an increase in cell 
number at or shortly after the same time. 
In contrast, IGF-I receptor RNA increases rapidly and 
continuously after removal of serum from IM-9 cells in 
culture. Such an increase in IGF-I receptor mRNA expres- 
sion might represent a compensatory up-regulatory mecha- 
nism at the receptor mRNA level. IGF-I I /M6P receptor 
and beta-actin RNA also increase after serum withdrawal. 
However, these changes are more subtle and occur at a 
slower rate. It is interesting to note that the maximal 
content of IGF-I receptor transcripts in IM-9 cells in serum 
free culture was measured 24-48 h after removal of serum. 
It was at the same time point that cell numbers had 
increased significantly. 
Suzuki et al. have previously reported that GH increases 
transcription of the GH receptor gene in IM-9 cells and 
also stimulates growth of IM-9 lymphoblasts [25]. It is 
known that IM-9 cells synthesize and secrete GH under 
certain culture conditions and that increased GH secretion 
is observed upon stimulation of cells with GH [26]. In 
contrast, we did not detect any effect of hGH on gene 
transcription in IM-9 cells under the conditions of our 
experiments. Our results are in agreement with the data 
from Clayton et al. who did not find any effect of hGH on 
IGF-I gene expression in IM-9 lymphoblasts [24]. We 
assume that either differences in culture conditions or the 
clones of IM-9 lymphoblasts used in the different studies 
may be responsible for this discrepancy. We hypothesize 
that under the conditions of our experiments serum fac- 
tors/substrates other than GH, IGF-I and II-1 beta regulate 
IGF-I, IGF-I receptor, GH receptor and IGF-I I /M6P re- 
ceptor RNA. 
GH and the IGFs have been implicated as playing a role 
in the proliferation of T-lymphocytes in vitro [28]; such 
changes might also directly influence the proliferative 
response of IM-9 cells in culture. Growth hormone and 
insulin have been shown to induce a rapid down-regulation 
ot GH receptors and insulin receptors in IM-9 lympho- 
blasts [29]. Conversely, IGF-II and a monoclonal antibody 
against he T-cell receptor have been shown to up-regulate 
IGF-I receptor specific binding of 125I-IGF-I in IM-9 cells 
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or IGF-I receptor RNA content in peripheral T-lympho- 
cytes [14,17]. Other hormones uch as human chorionic 
gonadotropin have been shown to induce IGF-I receptor 
gene expression [30-32] or down-regulate IGF-I receptor 
RNA [33,34]. Developmental regulation of the IGF-I re- 
ceptor and the IGF-II/M6P receptor gene has been de- 
scribed [9,15,35]. 
Both inhibitory and stirnulatory effects of sera upon 
IGF gene transcription have been described [36]. A bidirec- 
tional effect of serum removal upon IGF-I RNA expres- 
sion was measured in our study. It is conceivable that 
removal of serum from the IM-9 cells leads to a rapid 
decline in IGF-I RNA expression through the withdrawal 
of a stimulatory factor. A number of hormones including 
growth hormone have been described to stimulate IGF-I 
gene transcription i other cells [1,27,37,38]. 
It has been reported that both IGF-II and IGF-II/M6P 
receptor levels increase during skeletal muscle differentia- 
tion. In addition, IGF-II/M6P receptor gene expression is
increased uring compensatory growth of hepatic, renal 
and thyroid tissue and during endochondrial bone develop- 
ment [7,9,11,15,39,40]. Since the IGF-II/M6P receptor 
does not serve as a signal transduction pathway for the 
IGFs [41] but rather ser~'es to direct the transport of 
lysosomal enzymes to the; lysosome [7,10], changes in 
IGF-II/M6P receptor gene expression during cellular pro- 
liferation might not be directly related to growth and 
proliferation but rather be important for lysosomal enzyme 
function. 
In summary, we have observed that the genes encoding 
IGF-I, the IGF-I receptor, the IGF-II/M6P receptor and 
the GH receptor are differentially regulated in IM-9 lym- 
phoblasts. The mechanisms by which expression of these 
genes is being regulated are not known but are thought o 
involve a number of different ranscription factors such as 
the WT1 Wilms tumor gene product [42]. 
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